强脉冲光治疗慢性移植物抗宿主病患者睑板腺功能障碍的疗效和安全性。
Therapeutic Efficacy and Safety of Intense Pulsed Light for Meibomian Gland Dysfunction in Patients with Chronic Ocular Graft-Versus-Host Disease.
机构信息
State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Sun Yat-sen University, Guangzhou, China.
出版信息
Ocul Immunol Inflamm. 2024 Oct;32(8):1599-1608. doi: 10.1080/09273948.2023.2266763. Epub 2023 Oct 20.
PURPOSE
To evaluate the efficacy and safety of intense pulsed light combined with meibomian gland expression (IPL-MGX) for treating meibomian gland dysfunction (MGD) associated with chronic ocular graft-versus-host disease (oGVHD).
METHODS
This retrospective study included 18 patients (18 eyes) with Fitzpatrick skin type ≤ IV, who underwent 3 to 8 sessions of IPL-MGX. Dry eye symptomology, ocular surface parameters, and adverse events were evaluated.
RESULTS
Of 18 eyes, 83.3% and 66.7% showed severe oGVHD and severe MGD, respectively. At 4 weeks after the final session, significant improvements in the OSDI ( < 0.001), SPEED ( = 0.001), meibum expressibility ( < 0.001), and meibum quality ( = 0.016) were observed. At 12 weeks after, the OSDI ( = 0.009), SPEED ( = 0.002), and meibum expressibility ( = 0.008) significantly improved. No adverse events owing to IPL were reported.
CONCLUSION
IPL-MGX may improve the ocular symptoms, ameliorate meibomian gland secretion, and is considered as a safe treatment for MGD in oGVHD patients.
目的
评估强脉冲光联合睑板腺按摩（IPL-MGX）治疗慢性移植物抗宿主病（oGVHD）相关睑板腺功能障碍（MGD）的疗效和安全性。
方法
本回顾性研究纳入了 18 名（18 只眼）Fitzpatrick 皮肤类型≤IV 的患者，他们接受了 3 至 8 次 IPL-MGX 治疗。评估干眼症状、眼表参数和不良反应。
结果
18 只眼中，83.3%和 66.7%分别为严重 oGVHD 和严重 MGD。末次治疗后 4 周，OSDI（<0.001）、SPEED（=0.001）、睑脂排出量（<0.001）和睑脂质量（=0.016）显著改善。12 周后，OSDI（=0.009）、SPEED（=0.002）和睑脂排出量（=0.008）显著改善。未报告因 IPL 引起的不良反应。
结论
IPL-MGX 可能改善眼部症状，改善睑板腺分泌功能，被认为是 oGVHD 患者 MGD 的安全治疗方法。
Zotero 插件